DZIP3: A Zinc Finger Protein as a Drug Target and Biomarker (G9666)

Target Name: DZIP3

NCBI ID: G9666

DZIP3

DZIP3: A Zinc Finger Protein as a Drug Target and Biomarker

DAZ interacting protein 3 (DZIP3) is a protein that has been identified as a potential drug target and biomarker. DZIP3 is a zinc finger protein that is expressed in various tissues and cells throughout the body. It plays a critical role in cell signaling, and its dysfunction has been linked to various diseases, including cancer, neurodegenerative disorders, and developmental defects.

The DZIP3 gene

The DZIP3 gene is located on chromosome 16 at position 112.2 and has a protein coding domain of 198 amino acids. DZIP3 is a member of the Dazl family of proteins, which are known for their ability to interact with DNA and regulate gene expression.

Function and localization

DZIP3 is a protein that is expressed in various tissues and cells throughout the body, including the brain, heart, skeletal muscles, and organs. It is highly expressed in the brain, and its levels are decreased in aging brain tissues. DZIP3 is also expressed in the liver, kidneys, and other organs. It is localized to the nuclear envelope, where it interacts with various nuclear proteins, including histone modifications and nuclear transport proteins.

DZIP3 functions as a protein that can modulate gene expression and cell signaling pathways. It has been shown to play a role in the regulation of cell adhesion, migration, and invasion. DZIP3 has also been shown to interact with various proteins, including the transcription factor, p53, and the protein kinase, ABAQ.

DZIP3 as a drug target

DZIP3 has been identified as a potential drug target due to its unique function and its involvement in various diseases. One of the reasons for its potential as a drug target is its modulation by various signaling pathways. DZIP3 has been shown to play a role in cell signaling pathways, including the regulation of cell adhesion, migration, and invasion.

DZIP3 has also been shown to interact with various proteins, including the transcription factor, p53, and the protein kinase, ABAQ. These interactions suggest that DZIP3 may be a target for drugs that can modulate its function and activity.

Another reason for DZIP3's potential as a drug target is its expression profile in different tissues. DZIP3 is highly expressed in the brain, and its levels are decreased in aging brain tissues. This suggests that DZIP3 may be a target for drugs that can modulate its expression and activity in aging brain tissues.

DZIP3 as a biomarker

DZIP3 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects. DZIP3 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that DZIP3 may be a potential target for drugs that can modulate its expression in cancer cells.

DZIP3 has also been shown to be expressed in neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This suggests that DZIP3 may be a potential target for drugs that can modulate its expression in neurodegenerative disorders.

DZIP3 has also been shown to be expressed in developmental defects, such as Down syndrome and Fragile X syndrome. This suggests that DZIP3 may be a potential target for drugs that can modulate its expression in developmental

Protein Name: DAZ Interacting Zinc Finger Protein 3

Functions: E3 Ubiquitin ligase proteins mediate ubiquitination and subsequent proteasomal degradation of target proteins. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Able to specifically bind RNA

The "DZIP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DZIP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets